KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Research & Development (2016 - 2025)

Historic Research & Development for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $198.2 million.

  • Jazz Pharmaceuticals' Research & Development fell 85.83% to $198.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $828.6 million, marking a year-over-year decrease of 366.4%. This contributed to the annual value of $884.0 million for FY2024, which is 404.19% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Research & Development stood at $198.2 million for Q3 2025, which was down 85.83% from $190.0 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Research & Development peaked at $240.5 million during Q4 2024, and registered a low of $76.6 million during Q1 2021.
  • Over the past 5 years, Jazz Pharmaceuticals' median Research & Development value was $189.7 million (recorded in 2023), while the average stood at $178.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Research & Development skyrocketed by 7932.79% in 2021, and later plummeted by 1471.11% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Research & Development (Quarter) stood at $155.4 million in 2021, then increased by 11.01% to $172.6 million in 2022, then increased by 25.53% to $216.6 million in 2023, then grew by 11.03% to $240.5 million in 2024, then dropped by 17.59% to $198.2 million in 2025.
  • Its Research & Development was $198.2 million in Q3 2025, compared to $190.0 million in Q2 2025 and $240.5 million in Q4 2024.